A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection (Q57088820)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 February 2011

Language	Label	Description	Also known as
English	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection	scientific article published on 01 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

David Cunningham

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Y Barbachano

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

C Saffery

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

T Hickish

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

S Mudan

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Khan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A Wotherspoon

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

A S Strimpakos

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J Thomas

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

S Compton

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Y J Chua

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

I Chau

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

2042-2048

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Bevacizumab-associated gastrointestinal perforation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ714

21 January 2018

Identifiers

10.1093/ANNONC/MDQ714

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285134%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57088820&oldid=1997331497"